文献速递冠心病血脂与心血管预防

慢性冠脉综合征二级预防中终身阿司匹林:仍神圣不可侵犯还是需要重新评估?

Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted?
PubMed 文献 · Circulation · 2020-09-04

这是一篇叙述性综述,回顾阿司匹林在心肌梗死二级预防中的历史证据,并结合近期在经皮冠状动脉介入治疗后早期停用双联抗血小板治疗中的阿司匹林成分、慢性冠脉综合征合并房颤需抗凝时停用阿司匹林等特定临床场景的试验数据,对慢性冠脉综合征患者终身使用阿司匹林的必要性提出不确定性。近期一级预防试验在当代最佳心血管危险因素控制下未能一致显示阿司匹林净获益,提示随着现代二级预防治疗的增加,阿司匹林对慢性冠脉综合征二级预防的疗效可能也已改变。综述支持进一步研究所有慢性冠脉综合征成人二级预防中终身阿司匹林的普遍必要性,尤其是出血风险最高的稳定老年患者。

要点

  • 心肌梗死后急性期阿司匹林获益仍无可争议。
  • 特定场景停用阿司匹林的最新试验对慢性冠脉综合征终身用药提出挑战。
  • 稳定老年患者阿司匹林所致出血风险最高,需重新评估终身用药必要性。

核心结论

  • 近期证据对全部慢性冠脉综合征患者终身使用阿司匹林的必要性提出不确定性,支持进一步研究其普遍必要性。

研究设计与样本

  • 叙述性综述,汇总阿司匹林在心肌梗死二级预防中的历史试验及近期相关试验证据。

主要发现

  • 经皮冠状动脉介入治疗后早期停用双联抗血小板治疗中阿司匹林成分的试验数据挑战阿司匹林在慢性冠脉综合征中的既往地位。
  • 慢性冠脉综合征合并房颤需抗凝的患者中停用阿司匹林的数据同样挑战其既往地位。
  • 近期一级预防试验在当代最佳心血管危险因素控制下未能一致显示阿司匹林净获益。

临床怎么用

  • 对慢性冠脉综合征患者终身阿司匹林策略需个体化评估,尤其关注稳定老年患者的出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Four decades have passed since the first trial suggesting the efficacy of aspirin in the secondary prevention of myocardial infarction. Further trials, collectively summarized by the Antithrombotic Trialists' Collaboration, solidified the historical role of aspirin in secondary prevention. Although the benefit of aspirin in the immediate phase after a myocardial infarction remains incontrovertible, a number of emerging lines of evidence, discussed in this narrative review, raise some uncertainty as to the primacy of aspirin for the lifelong management of all patients with chronic coronary syndrome (CCS). For example, data challenging the previously unquestioned role of aspirin in CCS have come from recent trials where aspirin was discontinued in specific clinical scenarios, including early discontinuation of the aspirin component of dual antiplatelet therapy after percutaneous coronary intervention and the withholding of aspirin among patients with both CCS and atrial fibrillation who require anticoagulation. Recent primary prevention trials have also failed to consistently demonstrate net benefit for aspirin in patients treated to optimal contemporary cardiovascular risk factor targets, indicating that the efficacy of aspirin for secondary prevention of CCS may similarly have changed with the addition of more modern secondary prevention therapies. The totality of recent evidence supports further study of the universal need for lifelong aspirin in secondary prevention for all adults with CCS, particularly in stable older patients who are at highest risk for aspirin-induced bleeding.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Jacobsen AP, Raber I, McCarthy CP, et al. Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted? Circulation. 2020. PMID: 32886529. doi:10.1161/CIRCULATIONAHA.120.045695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。